Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database
Tóm tắt
The aim of this study was to evaluate the risk of acute myocardial infarction in patients taking osteoporosis medication. Patients were taken from the SIDIAP or CPRD database and were matched using propensity scores. Patients with diabetes and chronic kidney disease taking SERMs were at an increased risk. The results favour the cardiovascular safety of alendronate as a first-line choice for osteoporosis treatment. This study aims to evaluate the comparative safety of anti-osteoporosis drugs based on the observed risk of acute myocardial infarction while on treatment in a primary care setting. This is a propensity-matched cohort study and meta-analysis. This study was conducted in two primary care record databases covering UK NHS (CPRD) and Catalan healthcare (SIDIAP) patients during 1995–2014 and 2006–2014, respectively. The outcome was acute myocardial infarction while on treatment. Users of alendronate (reference group) were compared to those of (1) other oral bisphosphonates (OBP), (2) strontium ranelate (SR), and (3) selective oestrogen receptor modulator (SERM), after matching on baseline characteristics (socio-demographics, fracture risk factors, comorbidities, and concomitant drug use) using propensity scores. Multiple imputation was used to handle missing data on confounders and competing risk modelling for the calculation of relative risk (sub-distribution hazard ratios (SHR)) according to therapy. Country-specific data were analysed individually and meta-analysed. A 10% increased risk of acute myocardial infarction was found in users of other bisphosphonates as compared to alendronate users within CPRD. The meta-analysis of CPRD and SIDIAP results showed a 9% increased risk in users of other bisphosphonate as compared to alendronate users. Sensitivity analysis showed SERMS users with diabetes and chronic kidney disease were at an elevated risk. This study provides additional data on the risk of acute myocardial infarction in patients receiving osteoporosis treatment. The results favour the cardiovascular safety of alendronate as a first-line choice for osteoporosis treatment.
Tài liệu tham khảo
Sambrook P, Cooper C (2006) Osteoporosis. Lancet (London, England) 367(9527):2010–2018. https://doi.org/10.1016/S0140-6736(06)68891-0
National Institute for Health and Care Excellence (NICE) (2008) Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. http://www.laalamedilla.org/GUIAS/Guia%20NICE%20osteoporosis%20P12011.pdf
Kang J-HJ-H, Keller JJ, Lin H-CH-C (2012) A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke. Osteoporos Int 23:2551–2557. https://doi.org/10.1007/s00198-012-1894-0
Huang B, Huang F, Gui Y et al (2015) Association between bisphosphonates therapy and incident myocardial infarction: meta-analysis and trial sequential analysis. J Cardiovasc Pharmacol 66:168–477
Kim DH, Rogers JR, Fulchino LA et al (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS ONE 10:e0122646. https://doi.org/10.1371/journal.pone.0122646
European Medicines Agency (2013) Protelos-H-C-560-PSU-31: EPAR. Assessment report. Periodic safety update report. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000560/WC500147168.pdf
Bolland MJ, Grey A (2016) Ten years too long: strontium ranelate, cardiac events, and the European Medicines Agency. BMJ (Clinical research ed.) 354:i5109. https://doi.org/10.1136/bmj.i5109
Cooper C, Fox KM, Borer JS (2014) Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD. Osteoporos Int 25:737–745
Abrahamsen B, Grove EL, Vestergaard P (2014) Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 25:757–762
Svanström H, Pasternak B, Hviid A (2014) Use of strontium ranelate and risk of acute coronary syndrome: cohort study. Ann Rheum Dis 73:1037–1043
Audran M, Jakob FJ, Palacios S et al (2013) A large prospective European cohort study of patients treated with strontium ranelate and followed up over 3 years. Rheumatol Int 33:2231–2239
▽ Strontium ranelate discontinued (2017) Drug and therapeutics bulletin. Advance online publication. https://doi.org/10.1136/dtb.2017.8.0507
Barrett-Connor E, Mosca L, Collins P et al (2002) Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. JAMA 355:125–137
Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD, MORE Investigators (Multiple Outcomes of Raloxifene Evaluation) (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287(7):847–857. https://doi.org/10.1001/jama.287.7.847
Lyles KW, Colón-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809
Reginster J-Y, Wilson KM, Dumont E et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816–2822
Ramos R, Ballo E, Marrugat J et al (2012) Validity for use in research on vascular diseases of the SIDIAP (Information System for the Development of Research in Primary Care): the EMMA study. Rev Esp Cardiol (Engl Ed) 65:29–37. https://doi.org/10.1016/j.recesp.2011.07.017
Herrett E, Gallagher AM, Bhaskaran K et al (2015) Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 44:827–836. https://doi.org/10.1093/ije/dyv098
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. (1993). Am J Med 94(6):646–650. https://doi.org/10.1016/0002-9343(93)90218-e
Austin PC (2008) The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 61:537–545. https://doi.org/10.1016/j.jclinepi.2007.07.011
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509. https://doi.org/10.1080/01621459.1999.10474144
Scrucca L, Santucci A, Aversa F (2007) Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl 40:381–387
Nichols M, Townsend N, Scarborough P, Rayner M (2012) European cardiovascular disease statistics 2012. European Heart Network, Brussels
Galbete C, Schwingshackl L, Schwedhelm C et al (2018) Evaluating Mediterranean diet and risk of chronic disease in cohort studies: an umbrella review of meta-analyses. Eur J Epidemiol 33:909–931. https://doi.org/10.1007/s10654-018-0427-3
Pittman CB, Davis LA, Zeringue AL et al (2014) Myocardial infarction risk among patients with fractures receiving bisphosphonates. Mayo Clin Proc 89:43–51
Sing C-W, Wong AYS, Kiel DP et al (2018) Association of alendronate and risk of cardiovascular events in patients with hip fracture. J Bone Miner Res 33:1422–1434. https://doi.org/10.1002/jbmr.3448
Synetos A, Toutouzas K, Benetos G et al (2014) No catheter based inhibition of arterial calcification by bisphosphonates in an experimental atherosclerotic rabbit animal model. Int J Cardiol 176:177–181
Vestergaard P (2012) Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and no. Calcif Tissue Int 90:22–29
European Medicines Agency (2013) EMA/258269/2013. Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) CHMP confirms recommendation from the PRAC. https://www.ema.europa.eu/en/documents/pressrelease/recommendation-restrict-use-protelos/osseor-strontium-ranelate_en.pdf
Bolland MJ, Grey A (2014) A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record. BMJ open 4(10):e005787. https://doi.org/10.1136/bmjopen-2014-005787
Atteritano M, Catalano A, Santoro D et al (2016) Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women. Endocrine 53:305–312. https://doi.org/10.1007/s12020-015-0721-8
Ensrud K, Genazzani AR, Geiger MJ et al (2006) Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol 97:520–527
Barrett-Connor E, Mosca L, Collins P et al (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125–137. https://doi.org/10.1056/NEJMoa062462
Lu PY, Hsieh CF, Tsai YW, Huang WF (Sep 2011) Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate. Clin Ther 33(9):1173–1179. https://doi.org/10.1016/j.clinthera.2011.07.012
Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60:128–136
Herrett E, Thomas SL, Schoonen WM et al (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Cinical Pharmacol 69:4–14
Varas-Lorenzo C, García-Rodríguez LA, Perez-Gutthann S, Duque-Oliart A (2000) Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation 101:2572–2578
Hammad TA, McAdams MA, Feight A et al (2008) Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 17:1197–1201
Normand S-LT, Sykora K, Li P et al (2005) Readers guide to critical appraisal of cohort studies: 3 Analytical strategies to reduce confounding. BMJ 330:1021–1023